13, 28-epoxy substituted ursane triterpenes and preparation method and application thereof
A novel 13,28-epoxy-substituted ursane-type triterpenoid was prepared by microbial transformation of arbutin, which solved the problems of natural resource limitations and the randomness of chemical synthesis methods, and achieved efficient preparation of drug components with anti-tumor activity, suitable for the treatment of various tumors.
Patent Information
- Application Number
- CN202411092483.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-09
AI Technical Summary
In existing technologies, the extraction and isolation of ursane-type triterpenes from plants is limited by the availability of natural resources. Chemical synthesis methods have complex structures and the transformation results are difficult to predict. Microbial transformation methods are random and it is difficult to select suitable strains.
Arbutin was transformed by microorganisms such as *Rhizopus dauricum*, *Rhizopus erectus*, and *Rhizopus racemosa*. The arbutin was purified by fermentation, extraction, reversed-phase silica gel column chromatography, and reversed-phase high-performance liquid chromatography. Epoxy groups were formed at the 13β and 28β positions of ursane with regioselectivity and stereoselectivity, and hydroxyl, carbonyl, or acetoxy groups were introduced at the 7β, 15α, 21β, 23, or 24 positions, resulting in a novel 13,28-epoxy-substituted ursane-type triterpenoid.
A novel ursane-type triterpenoid with significant antitumor activity was obtained. Its application in the preparation of antitumor drugs was verified by in vitro antitumor cell experiments. It is suitable for cervical cancer, leukemia, neuroblastoma, prostate cancer, liver cancer and colon cancer.
Smart Images

Figure BDA0004986967170000031 
Figure BDA0004986967170000073 
Figure BDA0004986967170000081
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and specifically relates to a 13,28-epoxy-substituted ursane-type triterpene and a preparation method and application thereof. Background Art
[0002] Ursane triterpenes, also known as α-amyrinane triterpenes, are a class of terpenoid compounds whose basic nucleus consists of 30 carbon atoms. Most of these triterpenes are derivatives of ursonic acid, and their A / B, B / C, and C / D rings are all trans structures, and the D / E ring is a cis structure. They mainly exist in the form of free or glycosides in plants of the Rosaceae, Caprifoliaceae, and Oleaceae, such as Golden Cherry Root, Evergreen, and Centella Asiatica, including compounds such as α-amyrin, ursolic acid, and taraxasterol. Glycosides are generally substituted with hydroxyl groups at position 3 and carboxyl groups at position 28, and the substituted monosaccharides are mostly glucose, arabinose, rhamnose, glucuronic acid, etc. Modern pharmacological studies have shown that these compounds have anti-tumor, antioxidant, anti-inflammatory, antibacterial, hypoglycemic, and liver-protecting activities, and are widely used in the fields of medicine and cosmetics. At present, the main method for obtaining such triterpenoid compounds is direct extraction and separation from plants, and chemical synthesis or semi-synthesis is performed on this basis to obtain their derivatives.
[0003] However, direct extraction and separation from plants is limited by the supply of natural resources; chemical synthesis and chemical semi-synthesis of terpenoids have their complex structures, multiple stereo centers, the number of hydrogen bond donors in the mother nucleus and the number of rotatable bonds in the rigid skeleton, which limit people's further chemical and biological research. In recent years, with the rise of synthetic biology technology, the use of microbial transformation is a simple and effective technology for structural modification of natural compounds. It can introduce functional groups regioselectively and stereoselectively, and has the advantages of high efficiency, economy and environmental protection, which is difficult to achieve with conventional chemical modification. However, compared with chemical synthesis, the method of microbial transformation has great randomness, and the results of transformation cannot be predicted like chemical synthesis, nor can it be designed purposefully. At the same time, even similar substrates can be catalytically transformed by the same strain or different strains, and the products obtained can also be very significantly different. And the transformation products obtained by the same substrate after transformation by different strains may also be very significantly different. Therefore, it is crucial to choose the right strain when using microbial transformation to modify the structure of compounds. Summary of the invention
[0004] In view of this, the purpose of the present invention is to provide a 13,18-epoxy-substituted ursane-type triterpenoid or its pharmaceutically acceptable salt and a method for preparing the same by microbial transformation. At the same time, these ursane-type triterpenoids can be used to prepare anti-tumor drugs.
[0005] The 13,18-epoxy-substituted ursane type triterpenes provided by the present invention are 3β,7β,15α,21β-tetrahydroxy-13β,28β-epoxy-10-double bond-ursane, 3β,15α,21β-trihydroxy-13β,28β-epoxy-10-double bond-ursane, 3β,7β-dihydroxy-21β-acetoxy-13β,28β-epoxy-10-double bond-ursane, 7β,15α,21β-trihydroxy-3β-acetoxy-13β,28β-epoxy-10-double bond-ursane, 7β,21β-dihydroxy-3-carbonyl-13β,28β-cyclopentane Oxygen-10-double bond-ursane, 3β,7β,21β-trihydroxy-28-methoxy-13β,28β-epoxy-10-double bond-ursane, 3β,7β,15α,21β,23-pentahydroxy-13β,28β-epoxy-10-double bond-ursane, 3β,7β,21β,24-tetrahydroxy-13β,28β-epoxy-10-double bond-ursane and 3β,7β,24-trihydroxy-21-carbonyl-13β,28β-epoxy-10-double bond-ursane, the structures of which are shown in Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII and Formula IX, respectively:
[0006]
[0007] The compounds with structural formulas of formula I to formula IX are all novel ursane-type triterpenes disclosed for the first time in the present invention.
[0008] The present invention also provides a method for preparing the novel ursane-type triterpenes through microbial transformation, comprising the following steps:
[0009] 1) fermenting and culturing microorganisms, adding ursolic acid to the culture medium, then performing transformation culture, removing mycelium to obtain a fermentation liquid, wherein the microorganisms are Actinomucor elegans CGMCC 3.3393, Mucor erectus CGMCC 3.180, and Mucor racemosus CGMCC 3.20;
[0010] 2) extracting the fermentation broth to obtain a transformant;
[0011] 3) purifying the transformation product by reverse phase silica gel column chromatography, wherein the reverse phase silica gel column purification adopts a methanol-water two-phase system gradient elution, and collecting and merging the components;
[0012] 4) purifying the components by reverse phase high performance liquid chromatography to obtain 3β,7β,15α,21β-tetrahydroxy-13β,28β-epoxy-10-double bond-ursane, 3β,15α,21β-trihydroxy-13β,28β-epoxy-10-double bond-ursane, 3β,7β-dihydroxy-21β-acetoxy-13β,28β-epoxy-10-double bond-ursane, 7β,15α,21β-trihydroxy-3β-acetoxy-13β,28β-epoxy-10-double bond-ursane, 7β,21β-dihydroxy , 3β,7β,21β-trihydroxy-28-methoxy-13β,28β-epoxy-10-double bond-ursane, 3β,7β,15α,21β,23-pentahydroxy-13β,28β-epoxy-10-double bond-ursane, 3β,7β,21β,24-tetrahydroxy-13β,28β-epoxy-10-double bond-ursane and 3β,7β,24-trihydroxy-21-carbonyl-13β,28β-epoxy-10-double bond-ursane.
[0013] The present invention also provides the use of the novel ursane-type triterpenes in the preparation of anti-tumor drugs, wherein the tumor includes one of cervical cancer, leukemia, neuroblastoma, prostate cancer, liver cancer, breast cancer and colon cancer.
[0014] Compared with the prior art, the present invention utilizes the catalytic action of microbial enzymes to regioselectively and stereoselectively form epoxy groups at the 13β and 28β positions of ursane, and simultaneously introduces hydroxyl, carbonyl or acetoxy groups at the 7β, 15α, 21β, 23 or 24 positions. Thus, novel 13,28-epoxy-substituted ursane-type triterpenes of formula I to formula IX are obtained, and in vitro anti-tumor cell tests confirm that the compounds of formula I to formula IX have significant anti-tumor activity, can be used as active ingredients of anti-tumor drugs, and have a wide range of uses. DETAILED DESCRIPTION
[0015] To further illustrate the present invention, the preparation method of the novel 13,28-epoxy-substituted ursane-type triterpenes provided by the present invention and their application in the preparation of anti-tumor drugs are described in detail below in conjunction with examples.
[0016] Example 1: Preparation of novel ursane-type triterpenes having structural formulas of Formula I to Formula IX
[0017] The present invention adopts a microbial transformation method, uses ursolic acid as a substrate, and prepares the compound of the present invention through steps of biotransformation, extraction, separation, etc. Taking Actinomucor elegans CGMCC 3.3393 as an example, the process of preparing the compounds of formula I to formula IX is as follows:
[0018] 1) Microbial transformation
[0019] Preparation of seed solution: Pour the high-pressure sterilized PDB culture medium into two 250mL conical flasks, each containing 100mL of culture medium. Hook out some mycelium of the screened strain Actinomucor elegans CGMCC3.3393 and put it into the culture medium of the conical flask. Plug the mouth of the conical flask with gauze and bandage it. Place it in a constant temperature oscillator at 25℃ and 160rpm and culture it for 24 hours for use.
[0020] Amplification culture: Pour the autoclaved PDB medium into 1L conical flasks, each containing 400mL of medium, for a total of 60 flasks. At the same time, add about 1mL of the above seed solution to each conical flask, plug the bottle mouth with gauze and wrap it, and culture it in a constant temperature oscillator at 25℃ and 160rmp for 24h. When the strain is observed to grow to the logarithmic phase, add 20mg of arbutin (dissolved in anhydrous ethanol, about 2mL) to each conical flask and continue to culture it in a constant temperature oscillator for one week.
[0021] 2) Extraction, separation and purification
[0022] After 7 days of cultivation, the bacterial solution was filtered with four layers of non-woven gauze and extracted three times with an equal amount of ethyl acetate. The ethyl acetate layer was collected and concentrated by evaporation to obtain 2.14 g of a crude product.
[0023] The crude product was dissolved in methanol and roughly filtered, and then the crude product was initially separated in an ODS-C18 open column (column size: 60 cm × 3 cm, ODS-C18 size: 50 μm × 100 g). The initial separation used methanol: water (10:90, 40:60, 60:40, 80:20, 90:10, 100:0) as the mobile phase for gradient elution. The eluted components were combined by thin layer chromatography and analytical high performance liquid chromatography to obtain a total of 4 fractions (AD). Each fraction was further separated and prepared by semi-preparative high performance liquid chromatography.
[0024] Fraction B (127.7 mg) was treated with acetonitrile: water (65:35, flow rate 3.0 mL / min) as the mobile phase to obtain a compound with the structural formula III.
[0025] Fraction D (174.2 mg) used acetonitrile: water (35:65, flow rate 3.0 mL / min) as the mobile phase to obtain compounds with the structural formulas of Formula I, Formula II, Formula IV to Formula IX.
[0026] The high-resolution mass spectra and NMR data of compounds of formula I to formula IX are shown below.
[0027] Compound Ⅰ: 3β,7β,15α,21β-tetrahydroxy-13β,28β-epoxy-10-double bond-ursane; optical rotation +31.5°(c0.11,MeOH); high resolution mass spectrum m / z533.3495[M+COOH] - (ca l cd C 31 H 49 O7,533.3484); the H NMR and C NMR data are shown in Table 1.
[0028] Compound II: 3β,15α,21β-trihydroxy-13β,28β-epoxy-10-double bond-ursane; optical rotation +26.8°(c0.12,MeOH); high resolution mass spectrum m / z517.3526[M+COOH] - (ca l cd C 31 H 49 O6,517.3535); the H NMR and C NMR data are shown in Table 1.
[0029] Compound III: 3β,7β-dihydroxy-21β-acetoxy-13β,28β-epoxy-10-double bond-ursane; optical rotation +33.1°(c 0.12,MeOH); high resolution mass spectrum m / z 537.3555[M+Na] + (ca l cd C 32 H 50 O5Na, 537.3556); the H NMR and C NMR data are shown in Table 1.
[0030] Compound IV: 7β,15α,21β-trihydroxy-3β-acetoxy-13β,28β-epoxy-10-double bond-ursane; optical rotation +20.2°(c0.11,MeOH); high resolution mass spectrum m / z553.3498[M+Na] + (ca l cd 553.3505,C 32 H 50 O6Na); the H NMR and C NMR data are shown in Table 2.
[0031] Compound V: 7β,21β-dihydroxy-3-carbonyl-13β,28β-epoxy-10-double bond-ursane; optical rotation +15.6°(c0.14,MeOH); high resolution mass spectrum m / z515.3370[M+COOH] - (ca l cd C 31 H 47O6,515.3378); the H NMR and C NMR data are shown in Table 2.
[0032] Compound VI: 3β,7β,21β-trihydroxy-28-methoxy-13β,28β-epoxy-10-double bond-ursane; optical rotation +35.4°(c0.12,MeOH); high resolution mass spectrum m / z503.3732[M+H] + (ca l cd C 31 H 51 O5,503.3731); the H NMR and C NMR data are shown in Table 2.
[0033] Compound VII: 3β,7β,15α,21β,23-pentahydroxy-13β,28β-epoxy-10-double bond-ursane; optical rotation +38.7°(c0.11,MeOH); high resolution mass spectrum m / z527.3354[M+Na] + (ca l cd C 30 H 48 O6Na, 527.3349); the H NMR and C NMR data are shown in Table 3.
[0034] Compound VIII: 3β,7β,21β,24-tetrahydroxy-13β,28β-epoxy-10-double bond-ursane; optical rotation +48.2°(c 0.12,MeOH); high resolution mass spectrum m / z 533.3472[M+COOH] - (ca l cd C 31 H 49 O7,533.3484); the H NMR and C NMR data are shown in Table 3.
[0035] Compound IX: 3β,7β,24-trihydroxy-21-carbonyl-13β,28β-epoxy-10-double bond-ursane; optical rotation +43.6°(c 0.13,MeOH); high resolution mass spectrum m / z 531.3322[M+COOH] - (ca l cd C 31 H 47 O7,5331.3327); the H NMR and C NMR data are shown in Table 3.
[0036] Table 1. H NMR and C NMR data of compounds of formula I to formula III
[0037]
[0038]
[0039] Table 2. H NMR and C NMR data of compounds of formula IV to VI
[0040]
[0041]
[0042] Table 3. H NMR and C NMR data of compounds of formula VII to IX
[0043]
[0044]
[0045] The above results show that the structures of the obtained compounds of formula I to formula IX are correct.
[0046] By adopting the above-mentioned microbial transformation method, novel ursane-type triterpenes with structural formulas of Formula I to Formula IX can also be obtained using Mucor erectus CGMCC 3.180 and Mucor racemosus CGMCC 3.20 as transformation strains respectively.
[0047] Example 2: Antitumor activity of novel ursane-type triterpenes of formula I to formula IX
[0048] 1) Experimental methods
[0049] The MTT method was used to determine the half inhibition rate IC of each compound on tumor cell lines. 50 The experimental method is as follows:
[0050] Tumor cells in the logarithmic growth phase were taken and the cell concentration was adjusted to 5×10 5 / mL, inoculated in a 96-well culture plate. The experiment set up a blank control group, a cell control group and a drug treatment group, wherein 100 μL of cell suspension was added to each well of the cell control group and the drug treatment group, and only the culture medium was added to the blank control group, 100 μL per well. After the tumor cells were pre-cultured in an incubator for 24 hours, different concentrations of the test drugs were added to make the final concentration of 0.1-100 μM, and the culture was continued for 48 hours. The absorbance (A) value at 570 nm was measured on a microplate reader according to the MTT method, and the inhibition rate was calculated [inhibition rate = (1-A value of the experimental group / A value of the control group) × 100%]. The experiment was repeated 3 times. SPSS11.5 software was used to make a regression equation to calculate the half inhibitory concentration (IC50) of each test sample on tumor cells for 48 hours. 50 ).
[0051] 2) Experimental results
[0052] According to the MTT test results, calculate the IC of the test sample for the above cells 50 The results are shown in Table 4.
[0053] Table 4. In vitro cytotoxic activity screening results of test samples
[0054]
[0055] The results show that the compounds of the present invention with the structural formulas of Formula I to Formula IX have good anti-tumor activity and can be used as active ingredients of anti-tumor drugs.
Claims
1. A 13,28-epoxy-substituted ursane-type triterpene derivative or a pharmaceutically acceptable salt thereof, characterized in that: The structural formula of the 13,28-epoxy-substituted ursane-type triterpene derivative is selected from any of the following structural formulas:
2. A method for preparing 13,28-epoxy-substituted ursane-type triterpene derivatives by microbial transformation, characterized in that: The microbial transformation preparation method is as follows: using ursolic acid as a substrate, and using Actinomucor elegans CGMCC3.3393 for microbial transformation to obtain the 13,28-epoxy-substituted ursane-type triterpene derivative.
3. Use of the 13,28-epoxy-substituted ursane triterpene derivative according to claim 1 or the 13,28-epoxy-substituted ursane triterpene derivative prepared by the microbial conversion preparation method according to claim 2 in the preparation of anti-tumor drugs.
4. The use according to claim 3, characterized in that: The tumor includes one of cervical cancer, leukemia, neuroblastoma, prostate cancer, liver cancer, breast cancer and colon cancer.
5. An anti-tumor drug, characterized in that: The active ingredient of the anti-tumor drug is an ursane-type triterpene derivative or a pharmaceutically acceptable salt thereof; the ursane-type triterpene derivative is 3β,7β,15α,21β-tetrahydroxy-13β,28β-epoxy-10-double bond-ursane, 3β,15α,21β-trihydroxy-13β,28β-epoxy-10-double bond-ursane, 3β,7β-dihydroxy-21β-acetoxy-13β,28β-epoxy-10-double bond-ursane, 7β,15α,21β-trihydroxy-3β-acetoxy-13β,28β-epoxy-10-double bond-ursane, 7β,21β-dihydroxy-3-carbonyl-13β,2 One or more of 8β-epoxy-10-double bond-ursane, 3β,7β,21β-trihydroxy-28-methoxy-13β,28β-epoxy-10-double bond-ursane, 3β,7β,15α,21β,23-pentahydroxy-13β,28β-epoxy-10-double bond-ursane, 3β,7β,21β,24-tetrahydroxy-13β,28β-epoxy-10-double bond-ursane and 3β,7β,24-trihydroxy-21-carbonyl-13β,28β-epoxy-10-double bond-ursane; the tumor includes one of cervical cancer, leukemia, neuroblastoma, prostate cancer, liver cancer, breast cancer and colon cancer.
Citation Information
Patent Citations
Asiatic acid microbial conversion derivative as well as preparation method and application thereof
CN116284199A
Application of ursane triterpenes in preparation of medicines for treating nervous system diseases
CN116602971A
Urbutic derivative, microbial conversion preparation method and application
CN116693593A
Ursane type triterpenoids and microbial conversion preparation method and application thereof
CN116715718A
Cited By
Application of arbutin derivative in preparation of medicine for preventing or treating osteoporosis
CN119818508A
